Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319757 · ClinicalTrials.gov registry record · Phase 1
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
A Phase 1 study, sponsored by Acepodia Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04319757 is a Phase 1 study that has completed, run by Acepodia Biotech. The registered enrollment target is 12 participants.
The verdict
NCT04319757, a Phase 1 study, has completed, sponsored by Acepodia Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG ACE1702
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-06-24 |
| Est. Completion | 2024-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04319757
The ClinicalTrials.gov registry entry for NCT04319757 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acepodia Biotech, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04319757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04319757 about?
NCT04319757 is a clinical study titled "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors". ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with adv...
What is the current status of trial NCT04319757?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-06-24. Estimated completion is 2024-07-15.
What interventions are being tested in trial NCT04319757?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), ACE1702 (DRUG).
Who is sponsoring clinical trial NCT04319757?
This trial is sponsored by Acepodia Biotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.